HCA Healthcare vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest US for-profit hospital network with ~190 hospitals; $70.7B FY2024 revenue; AI clinical decision support reducing preventable mortality; Sun Belt demographics advantage; NYSE: HCA.
About
HCA Healthcare is the largest for-profit hospital system in the United States, founded in 1968 by Jack Massey, Dr. Thomas Frist Sr., and Dr. Thomas Frist Jr. in Nashville, Tennessee, where it remains headquartered and trades on NYSE (HCA). The company operates approximately 190 hospitals and 2,400 ambulatory care sites—including surgery centers, physician clinics, and urgent care facilities—across 20 U.S. states and the United Kingdom, serving over 37 million patients annually. For FY2024, HCA generated approximately $70.7 billion in revenues under CEO Samuel Hazen, continuing a multi-year growth trajectory driven by hospital volume recovery, acuity mix improvement, and strategic investments in ambulatory care that intercept patients in lower-cost settings before they require inpatient hospitalization.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.